ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical is well positioned because its consumables-heavy, pure-play infusion therapy franchise serves a structurally defensive market, with over 60% of sales in the U.S. and top-tier positions across consumables, infusion systems, and vital care. The company is delivering broad-based execution, as 2Q revenue reached $551.7M, adjusted EBITDA hit a record $110M at a 20.1% margin, and adjusted EPS of $2.37 beat expectations on record consumables and infusion systems sales. Positive outlook drivers also include competitive share gains, improving gross margin to 41%, free cash flow inflection, and leverage falling to 2.3x, while FDA progress on Medfusion 5000 and a near-2x leverage target add further upside optionality.

ICU Medical is facing a fragile setup despite recent revenue improvement, because its 2Q26 growth was concentrated in Consumables and Infusion Systems while Vital Care still declined 4% and missed consensus, highlighting uneven end-market demand. The negative outlook is reinforced by management’s acknowledgment of pulled-forward pump installations, regulatory uncertainty around the amended 510(k) submission for Medfusion 5000 later this year, and the risk that revenue growth slows to low-single digits. With a bear case predicated on only limited operating margin improvement and gross margin pressure from inflation, tariffs, pricing, and contract-renewal risk, earnings upside appears constrained.